Randomized phase II study evaluating AKT blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss

Clinical Cancer Research

Volumn 25, Issue 3, 2019, Pages 928-936

  De Bono, Johann S ⁱ   De Giorgi, Ugo ^a   Rodrigues, Daniel Nava ⁱ   Massard, Christophe ^b   Bracarda, Sergio ^c   Font, Albert ^d   Arija, Jose Angel Arranz ^e   Shih, Kent C ^f   Radavoi, George Daniel ^g   Xu, Na ^h   Chan, Wai Y ^h   Ma, Han ^h   Gendreau, Steven ^h   Riisnaes, Ruth ⁱ   Patel, Premal H ^h   Maslyar, Daniel J ^h   Jinga, Viorel ^g  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c IRCCS POLICLINICO SAN DONATO   (Italy)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f Tennessee Oncology   (United States)

^g CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^h GENENTECH INC   (United States)

ⁱ INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; IPATASERTIB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN KINASE B; 2-(4-CHLOROPHENYL)-1-(4-(7-HYDROXY-5-METHYL-6,7-DIHYDRO-5H-CYCLOPENTA(D)PYRIMIDIN-4-YL)PIPERAZIN-1-YL)-3-(ISOPROPYLAMINO)PROPAN-1-ONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PTEN PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE;

AGED; AKT SIGNALING; ARTICLE; ASTHENIA; BACKACHE; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL; VOMITING; CLINICAL TRIAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

AGED; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PIPERAZINES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; PYRIMIDINES; TREATMENT OUTCOME;

EID: 85058939236     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-18-0981     Document Type: Article

References (29)

1. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86.
2. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 2011;19:792-804.
3. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
4. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161:1215-28.
5. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15:4799-805.
6. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
7. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13: 983-92.
8. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013;32:5501-11.
9. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
10. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48.
11. Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012;25:902-10.
12. Ferraldeschi R, Nava Rodrigues D, Riisnaes R, Miranda S, Figueiredo I, Rescigno P, et al. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. Eur Urol 2015; 67:795-802.
13. Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 2012;12:543.
14. Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, et al. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer 2013;108:2582-9.
15. Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol 2012;25:1543-9.
16. Ahearn TU, Pettersson A, Ebot EM, Gerke T, Graff RE, Morais CL, et al. A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer. J Natl Cancer Inst 2015;108:pii:djv346.
17. Kim SH, Kim SH, Joung JY, Lee GK, Hong EK, Kang KM, et al. Over-expression of ERG and wild-type PTEN are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancer. PLoS One 2015;10:0122498.
18. Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res 2011;71:572-82.
19. Blake JF, Xu R, Bencsik JR, Xiao D, Kallan NC, Schlachter S, et al. Discovery and preclinical pharmacology of a selective ATP-competitive akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem 2012;55: 8110-27.
20. Lin J, Sampath D, Nannini MA, Lee BB, Degtyarev M, Oeh J, et al. Targeting activated akt with GDC-0068, a novel selective akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res 2013; 19:1760-72.
21. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al. Evaluation and clinical analyses of downstream targets of the akt inhibitor GDC-0068. Clin Cancer Res 2013;19:6976-86.
22. Saura C, Roda D, Rosello S, Oliveira M, Macarulla T, Perez-Fidalgo JA, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov 2017;7:102-13.
23. Sonpavde G, Pond GR, Armstrong AJ, Galsky MD, Leopold L, Wood BA, et al. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU Int 2014;114: E25-31.
24. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
25. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010;102:678-84.
26. Correia NC, Girio A, Antunes I, Martins LR, Barata JT. The multiple layers of non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer 2014;50:216-25.
27. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaem-manuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353-7.
28. Lotan TL, Carvalho FL, Peskoe SB, Hicks JL, Good J, Fedor HL, et al. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy. Mod Pathol 2015;28:128-37.
29. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, et al. Higher risk of infections with PI3K-AKT-mTOR pathway inhibitors in patients with advanced solid tumors on phase I clinical trials. Clin Cancer Res 2015;21: 1869-76.